Skip to main content

Table 3 Response to therapy of patients with grade 1, 2 and 3A

From: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

  N Total Mutated EZH2 in FFPE (n = 36) Unmutated EZH2 in FFPE (n = 105) p-valor
(n = 141)
Outcome, n (%)
First-line therapy, n (%) 141     
Treated   123 (87) 30 (83) 93 (89) 0.4
Watchful waiting 18 (13) 6 (17) 12 (11)
Progression   4 (3) 1 (2.8) 3 (2.9) 0.7
Transformation   4 (3) 1 (2.8) 3 (2.9) 0.7
POD24   13 (9.2) 4 (11.1) 9 (8.6) 0.4
Relapse   25 (17.8) 4 (11) 21 (20) 0.1
Death   22 (15.6) 2 (5.5) 20 (19) 0.034
R-Bendamustine 30 30 (24) 7 (23) 23 (25)  
  Complete remission   29 (97) 7 22 (96) 0.8
  Partial remission 0 0 0 NA
  Progression   1 (3.5) 0 1 (4.4) NA
  Transformation 0 0 0 NA
  POD24   4 (13.3) 2 (29) 2 (9) 0.2
  Relapse   4 (13.3) 2 (5.6) 2 (1.9) 0.2
  Death   4 (13.3) 1 (14.2) 3 (13) 0.7
R-CHOP 67 67 (55) 18 (60) 49 (52)  
  Complete remission   62 (93) 16 (89) 48 (98) 0.8
  Partial remission   1 (1.5) 0 1 (2) NA
  Not assesseda   2 (3) 2 (11) 0 NA
  Progression   0 0 0 NA
  Transformation 0 0 0 NA
  POD24   6 (9) 1 (5.5) 5 (10) 0.4
  Relapse   18 2 (11) 16 (32) 0.052
  Death   11 (16.5) 1 (2.8) 10 (9.5) 0.13
R-CVP, Rituximab and Radiotherapy 26 26 (21) 5 (17) 21 (23)  
  1. aData not included in Fisher’s exact test